Helio Genomics has joined forces with Syneos Health to promote HelioLiver™, a pioneering AI-driven blood test, for early liver cancer diagnosis across America.

Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.  […]

Discover how the HelioLiver™ multi-analyte blood test enhances early liver cancer detection compared to ultrasound, transforming patient care immensely.

Helio Genomics has partnered with Quest Diagnostics to make its HelioLiver™ test widely accessible for early liver cancer detection through Quest's extensive network.

Syneos Health's proven commercialization expertise to engage healthcare providers and expand access to HelioLiver™ for high-risk patients in the United States IRVINE, Calif., May 19, 2026 /PRNewswire/ -- Helio Genomics, a leading AI-powered TechBio company focused on revolutionizing early...

Prospective multicenter trial shows HelioLiver™ detects more, early hepatocellular carcinoma than abdominal ultrasound for high-risk patients with cirrhosis IRVINE, Calif., May 6, 2026 /PRNewswire/ -- Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today...

Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand HelioLiver adoption. Professional audiences only. Not investment research or […] The post Lucid Diligence Brief: Helio Genomics and Syneos Health Deal appeared first on LucidQuest Ventures.